Pharvaris N.V. Files Routine 6-K Report

TL;DR

Pharvaris N.V. filed a standard 6-K, no new info.

AI Summary

Pharvaris N.V. filed a Form 6-K on September 8, 2025, reporting for the month of September 2025. The company, previously known as Pharvaris, B.V., is a foreign private issuer incorporated in P7 and headquartered in Leiden, The Netherlands. This filing is routine and does not appear to contain specific financial updates or material events.

Why It Matters

This filing indicates Pharvaris N.V. is fulfilling its reporting obligations as a foreign private issuer. It does not contain new financial information or material business developments.

Risk Assessment

Risk Level: low — This is a routine filing that does not disclose new material information or financial performance.

Key Players & Entities

• Pharvaris N.V. (company) — Registrant
• Pharvaris, B.V. (company) — Former company name
• 001-40010 (other) — SEC File Number
• 2834 (other) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

From the Filing

0001193125-25-198423.txt : 20250908 0001193125-25-198423.hdr.sgml : 20250908 20250908165130 ACCESSION NUMBER: 0001193125-25-198423 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250908 FILED AS OF DATE: 20250908 DATE AS OF CHANGE: 20250908 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharvaris N.V. CENTRAL INDEX KEY: 0001830487 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: P7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40010 FILM NUMBER: 251300642 BUSINESS ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN PROVINCE COUNTRY: P7 BUSINESS PHONE: 31 (0)71 203 6410 MAIL ADDRESS: ADDRESS IS A NON US LOCATION: YES STREET 1: J.H. OORTWEG 21 STREET 2: 2333 CH LEIDEN CITY: LEIDEN PROVINCE COUNTRY: P7 FORMER COMPANY: FORMER CONFORMED NAME: Pharvaris, B.V. DATE OF NAME CHANGE: 20201029 6-K 1 d19198d6k.htm 6-K 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File Number: 001-40010 Pharvaris N.V. (Translation of registrant’s name into English) Emmy Noetherweg 2 2333 BK Leiden The Netherlands (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒   Form 40-F ☐ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐ Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐ Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. PHARVARIS N.V. On September 2, 2025, Pharvaris N.V. (the “Company”) entered into a registration rights agreement (the “Registration Rights Agreement”) with General Atlantic PH B.V. (the “Investor”) relating to the exercised pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 500,000 ordinary shares of the Company, par value €0.12 per share (the “Ordinary Shares”), which Pre-Funded Warrants were acquired by the Investor in an underwritten offering that closed on July 24, 2025. The Registration Rights Agreement contains customary registration rights, including demand registration rights, with respect to the Ordinary Shares, as well as customary indemnification provisions. The foregoing is a summary description of the Registration Rights Agreement and is qualified in its entirety by the text of the Registration Rights Agreement filed as Exhibit 99.1 to this Current Report on Form 6-K and incorporated herein by reference. This Report on Form 6-K shall be deemed to be incorporated by reference into the Company’s registration statements on Form F-3 (Registratio